Paper Details

  1. Home
  2. Paper Details

PARP inhibitors in ovarian cancer.

Author: LedermannJ A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article discusses the use of PARP inhibitors, specifically in ovarian cancer, as a targeted therapy. PARP inhibitors target DNA repair and are particularly effective in cells with impaired homologous recombination (HR) pathway function, including those with BRCA mutations.
Paper Details　
Original Abstract of the Article :
Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy. Poly(ADP-ribose) polymerase (PARP) inhibitors target DNA repair and are specifically active in cells that have impaired repair of DNA by the homo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/annonc/mdw094

データ提供：米国国立医学図書館（NLM）

PARP Inhibitors in Ovarian Cancer: A Targeted Approach to Treatment

This review delves into the use of poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer. The authors explain how these drugs target DNA repair pathways, specifically those that are deficient in cells with mutated BRCA genes. They discuss the potential of PARP inhibitors to effectively target ovarian cancer cells with impaired homologous recombination (HR), a key DNA repair pathway. The review also highlights the growing understanding of HR deficiency (HRD) in non-BRCA-mutated ovarian cancers.

PARP Inhibitors: A New Era in Ovarian Cancer Treatment

The review showcases the promise of PARP inhibitors as a targeted therapy for ovarian cancer. By exploiting the specific vulnerabilities of cancer cells with impaired DNA repair mechanisms, these drugs offer a potential avenue for more effective and less toxic treatment approaches. The growing understanding of HRD in non-BRCA-mutated ovarian cancers further expands the potential reach of PARP inhibitors in treating this challenging disease.

The Power of Precision Medicine in Cancer Care

This research highlights the power of precision medicine in cancer care. By targeting specific molecular vulnerabilities within cancer cells, PARP inhibitors represent a paradigm shift in the treatment of ovarian cancer. This personalized approach holds the potential for more effective and less toxic therapies, ultimately improving patient outcomes and quality of life.

Dr. Camel's Conclusion

This research, like a caravan discovering a hidden oasis in the desert, reveals the promise of PARP inhibitors as a targeted therapy for ovarian cancer. These drugs offer a potential breakthrough in treating this challenging disease, paving the way for more effective and less toxic treatment options. Remember, just as a camel adapts to the desert's challenges, we must embrace precision medicine to effectively combat cancer and improve patient care.

Date :
  1. Date Completed 2017-12-22
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

27141070

DOI: Digital Object Identifier

10.1093/annonc/mdw094

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.